Clinical Trial Search

Primary: Probability for Event Free Survival. — 0.8984; 0.7647; 0.6079; 0.4873 Probability of EFS at 5 years

Primary: Number of Patients With Abdominal Recurrence or Death — 72; 73; 61; 60 Participants — p=0.955

Primary: Number of Adverse Events of Grade ≥ 3 by CTCAE Criteria. — 8 events

Primary: Number of Participants With Overall Response (OR) — 1 participants

Primary: Pathologic Response Rate, Defined as the Percentage of Participants With Greater Than or Equal to 95% Necrosis. — 20 % of participants

Primary: Percentage of Participants With Objective Response — 0; 0; 0 percentage of participants

Primary: Progression-free Survival (PFS) (Arm 1 Only) — 5.48 months

Primary: Local Disease Control Assessed by Physical Examination — 0 Participants

Primary: Correlation Between Time to Next Treatment (TNT) and Overall Survival (OS) Under First-line Treatment — 0.76 correlation coefficient

Primary: Objective Response (Confirmed, Complete and Partial) — 1; 0; 1; 8 participants

Primary: Number of Dose Limiting Toxicities — 0; 2 DLTs

Primary: Change in Fludeoxyglucose (FDG) Uptake (Maximal Standardized Uptake Value, or SUVmax)

Primary: Overall Objective Response — 5; 22; 8 participants

Primary: Percentage of Patients With Low-risk Rhabdomyosarcoma in Subset 1 Failure Free at 5 Years Following Study Entry — 87; 67 Estimated percentage of participants

Primary: Cumulative Incidence (Estimated Percentage of Participants) Who Developed Toxicities Following Radiation Treatment — 17.7 percentage of participants

Primary: Clinical Benefit Rate — 22 Participants

Primary: Adherence Rate to Diagnosis Imaging Guidelines for Patients With a Deep Sarcoma Tumor (Before Implementation of the Public Health Intervention Programme. — 145…

Primary: Progression-free Survival — 83; 170 Days

Primary: Objective Tumor Response (Complete and Partial) — 2 Participants

Primary: Percentage of Patients With Progression-free Survival at 16 Weeks. — 36.4 Percentage of patients

Primary: Percentage of Participants Who Experienced Event-Free Survival (EFS) Events as Per Independent Review Committee (IRC) Assessment — 52.5; 68.9 percentage of participants

Primary: Response (Complete Response [CR] and Partial Response [PR]) — 1; 0; 0; 0 participants

Primary: Number of Patients With Dose Limiting Toxicities. — 0; 1; 0 Participants

Primary: Event Free Survival (EFS) — 0.6255; 0.5874 Probability

Primary: Response Rate for Amrubicin in Patients With Metastatic or Advanced Sarcoma as First Line Therapy. — 13 percentage of pt with a partial response

Primary: Objective Response by RECIST Criteria v 1.1 — 10; 10; 0; 0 participants

Primary: Response Rate (CR + PR) Assessed by RECIST 1.1 (Phase II) — 4; 1; 5; 0 participants

Primary: Best Overall Response Rates by Week 16 (ITT) — 0; 0; 0; 0 percentage of participants — p=0.1

Primary: Number of Participants With Engraftment — 23 Participants

Primary: Progression-free Survival — 1.8; 3.7 months